Sophiris Bio Inc. (NASDAQ:SPHS) shares rose 2.7% during trading on Friday . The company traded as high as $2.69 and last traded at $2.66, with a volume of 292,760 shares changing hands. The stock had previously closed at $2.59.

SPHS has been the topic of a number of analyst reports. Echelon Wealth Partners reissued a “buy” rating and set a $5.00 price objective on shares of Sophiris Bio in a report on Friday, June 10th. Maxim Group reaffirmed a “buy” rating and issued a $4.00 target price on shares of Sophiris Bio in a report on Friday, June 10th.

The stock’s 50 day moving average price is $1.87 and its 200-day moving average price is $1.64. The firm’s market cap is $55.37 million.

Sophiris Bio (NASDAQ:SPHS) last posted its earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.06. On average, equities research analysts forecast that Sophiris Bio Inc. will post ($0.73) earnings per share for the current fiscal year.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.